VMY-1-103
VMY-1-103 is a potent dansylated CDK inhibitor derived from purvalanol B. It demonstrates superior antiproliferative and pro-apoptotic activity in vitro against prostate, breast, and medulloblastoma cancer cells by inducing cell cycle arrest and activating intrinsic and extrinsic apoptotic pathways.
Product Specifications
CAS Number
1209002-43-6
Field of Research
Cell Biology, Protein Biochemistry
Smiles
N (C1=C2C (N (C (C) C) C=N2) =NC (N[C@H] (C (C) C) CO) =N1) C3=CC (Cl) =C (C (NCCNS (=O) (=O) C=4C5=C (C (N (C) C) =CC=C5) C=CC4) =O) C=C3
Molecular Formula
C34H42ClN9O4S
Molecular Weight
708.27
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC472117-500 1x 500 µL
ARF1 (Golgi Apparatus Marker) (ARF1/2117), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042505-500 1x 500 µL
CD73 (Immuno-Oncology Target) (NT5E/2505), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNCB1571-500 1x 500 µL
GCDFP-15 (Gross Cystic Disease Fluid Protein 15) (Breast Marker) (PIP/1571), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details